country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99225A

Copy Link Print Information

Biologically Validated

Mirvetuximab (powder)

(Synonyms: M9346A (powder))

2 Cited Publications

Avis client

Based on 2 publication(s) in Google Scholar

Mirvetuximab (M9346A) (powder) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab (powder) is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.87%
CAS No.: 1453084-36-0
Masse moléculaire:145.2 kDa

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Mirvetuximab (powder) Chemical Structure

CAS No.: 1453084-36-0

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Publications Citing Use of MedChemExpress (MCE) Mirvetuximab (powder)

Customer Validation & Images

In Vivo Efficacy StudyBio/Physico-chemical AssayHistological Imaging/StainingIn Vivo Imaging

Bio/Physico-chemical Assay
Bio/Physico-chemical Assay
In Vivo Imaging
In Vivo Efficacy Study
Histological Imaging/Staining

Activité biologique
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- In Vitro
- Essai clinique
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Application
- Verified Bioactivity
Chemical Information
Publications (2)
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

In Vitro

Mirvetuximab (0.17 pM-81 nM, 2 h) (powder) bounds three antibodies bound with high affinity, with EC₅₀ values in the double-digit picomolar range (14.3, 16.5, and 21.1 pM for binding to clones 4E12-G5, 4E12-B9, and 5D12-C11, respectively)^[2].
Mirvetuximab (1 pM-100 nM) (powder) shows dose-dependent binding to folate receptor in the absence of competing anti-idiotype antibodies^[2].
Mirvetuximab (1 pM-100 nM) (powder) associates with H2110 cells with an EC₅₀ of around 650 pM by specific binding of M9346A to surface folate receptor antigen^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

2348 [NCBI]

Accession

P15328

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Application

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized hu-FRα-ECD-his can bind Mirvetuximab (powder). The EC₅₀ for this effect is 17.26 ng/mL.

Chemical Information

CAS No. 1453084-36-0
Appearance Solid
Masse moléculaire 145.2 kDa
Color White to off-white
SMILES

[Mirvetuximab (powder)]
Synonyms

M9346A (powder)
Livraison

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All In Vivo Efficacy StudyBio/Physico-chemical AssayHistological Imaging/StainingIn Vivo Imaging

Sort by:

Journal Impact Factor

Chem Biomed Imaging

2025 Nov 17;XXXX(XXX).

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: Chem Biomed Imaging. 2025 Nov 17;XXXX(XXX).

Binding affinity experiments of Zr-DFO-Mirvetuximab (2 h) to the FRα protein were performed.

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: Chem Biomed Imaging. 2025 Nov 17;XXXX(XXX).

Cell uptake experiments were conducted with Zr-DFO-Mirvetuximab in CAL51 and MDA-MB-231 cells.

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: Chem Biomed Imaging. 2025 Nov 17;XXXX(XXX).

Micro-PET/CT imaging of CAL51 and MDA-MB-231 tumor models was performed at 24, 72, 96, 120, and 144 h p.i.
bioRxiv

FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer. [Abstract]

2025 Oct 27:2025.10.27.684721. PMID: 41279140

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 27:2025.10.27.684721. [Abstract]

Relative tumor volume of Mirvetuximab (4.5 mg/kg at Day 0 and Day 7 (i.v)) was measured.

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 27:2025.10.27.684721. [Abstract]

Histological evaluation of tumor tissues at the study end point was performed by H&E (Magnification 10X (top panel) and 40X (bottom panel); Scale bar: 100µm). Mirvetuximab (4.5 mg/kg at Day 0 and Day 7 (i.v.)) was administered.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (260 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Références

[1]. Moore KN, et al. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 1;35(10):1112-1118. [Content Brief]

[2]. Loebrich S, et al. Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. AAPS J. 2017 Jul;19(4):1223-1234. [Content Brief]

[3]. Ab O, et al. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Mol Cancer Ther. 2015 Jul;14(7):1605-13. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Mirvetuximab (powder)

2 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- In Vitro
- Essai clinique
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Application
- Biological Activity
Chemical Information
Publications (2)
Pureté et documentation
Références

1/16

Immobilized hu-FRα-ECD-his can bind Mirvetuximab (powder). The EC₅₀ for this effect is 17.26 ng/mL.
1/16

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: Chem Biomed Imaging. 2025 Nov 17;XXXX(XXX).

Customer Validation
Binding affinity experiments of Zr-DFO-Mirvetuximab (2 h) to the FRα protein were performed.
1/16

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: Chem Biomed Imaging. 2025 Nov 17;XXXX(XXX).

Customer Validation
Cell uptake experiments were conducted with Zr-DFO-Mirvetuximab in CAL51 and MDA-MB-231 cells.
1/16

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: Chem Biomed Imaging. 2025 Nov 17;XXXX(XXX).

Customer Validation
Micro-PET/CT imaging of CAL51 and MDA-MB-231 tumor models was performed at 24, 72, 96, 120, and 144 h p.i.
1/16

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 27:2025.10.27.684721. [Abstract]

Customer Validation
Relative tumor volume of Mirvetuximab (4.5 mg/kg at Day 0 and Day 7 (i.v)) was measured.
1/16

Mirvetuximab (powder) purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 27:2025.10.27.684721. [Abstract]

Customer Validation
Histological evaluation of tumor tissues at the study end point was performed by H&E (Magnification 10X (top panel) and 40X (bottom panel); Scale bar: 100µm). Mirvetuximab (4.5 mg/kg at Day 0 and Day 7 (i.v.)) was administered.
1/16

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Mirvetuximab (powder)

Antibody Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Mirvetuximab (powder)

Activité biologique

Chemical Information

Publications (2)

Pureté et documentation

Références

Calculators

Help & FAQs

Mirvetuximab (powder) Related Classifications

HY-P99225A Related Classifications